<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Neurosurgery Blog &#187; radiosurgery</title>
	<atom:link href="http://www.neurosurgery-blog.com/archives/category/radiosurgery/feed" rel="self" type="application/rss+xml" />
	<link>http://www.neurosurgery-blog.com</link>
	<description>Daily bibliographic and video review of the Neurosurgery Department. La Fe University Hospital. Valencia, Spain</description>
	<lastBuildDate>Thu, 09 Feb 2012 23:00:45 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.9.1</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Stereotactic radiosurgery for arteriovenous malformations, Part 6: multistaged volumetric management of large arteriovenous malformations</title>
		<link>http://www.neurosurgery-blog.com/archives/3692</link>
		<comments>http://www.neurosurgery-blog.com/archives/3692#comments</comments>
		<pubDate>Tue, 17 Jan 2012 23:00:25 +0000</pubDate>
		<dc:creator>cba</dc:creator>
				<category><![CDATA[Vascular]]></category>
		<category><![CDATA[radiosurgery]]></category>
		<category><![CDATA[Arteriovenous malformation]]></category>
		<category><![CDATA[complications]]></category>
		<category><![CDATA[Gamma Knife surgery]]></category>
		<category><![CDATA[large aneurysm]]></category>
		<category><![CDATA[staged radiosurgery]]></category>
		<category><![CDATA[Stereotactic radiosurgery]]></category>

		<guid isPermaLink="false">http://www.neurosurgery-blog.com/?p=3692</guid>
		<description><![CDATA[J Neurosurg 116:54–65, 2012. DOI: 10.3171/2011.9.JNS11177
The object of this study was to define the long-term outcomes and risks of arteriovenous malformation (AVM) management using 2 or more stages of stereotactic radiosurgery (SRS) for symptomatic large-volume lesions unsuitable for surgery.
Methods. In 1992, the authors prospectively began to stage the treatment of anatomical components to deliver higher [...]]]></description>
			<content:encoded><![CDATA[<p style="text-align: justify;"><strong><a href="http://www.neurosurgery-blog.com/wp-content/uploads/2012/01/Stereotactic-radiosurgery-for-arteriovenous-malformations_Part-6_.jpg"><img class="alignleft size-thumbnail wp-image-3693" title="Stereotactic radiosurgery for arteriovenous malformations_Part 6_" src="http://www.neurosurgery-blog.com/wp-content/uploads/2012/01/Stereotactic-radiosurgery-for-arteriovenous-malformations_Part-6_-150x150.jpg" alt="" width="150" height="150" /></a>J Neurosurg 116:54–65, 2012. DOI: 10.3171/2011.9.JNS11177</strong></p>
<p style="text-align: justify;">The object of this study was to define the long-term outcomes and risks of arteriovenous malformation (AVM) management using 2 or more stages of stereotactic radiosurgery (SRS) for symptomatic large-volume lesions unsuitable for surgery.</p>
<p style="text-align: justify;">Methods. In 1992, the authors prospectively began to stage the treatment of anatomical components to deliver higher single doses to AVMs with a volume of more than 10 cm3. Forty-seven patients with such AVMs underwent volume-staged SRS. In this series, 18 patients (38%) had a prior hemorrhage and 21 patients (45%) underwent prior embolization. The median interval between the first-stage SRS and the second-stage SRS was 4.9 months (range 2.8–13.8 months). The median target volume was 11.5 cm3 (range 4.0–26 cm3) in the first-stage SRS and 9.5 cm3 in the second-stage SRS. The median margin dose was 16 Gy (range 13–18 Gy) for both stages.</p>
<p style="text-align: justify;">Results. In 17 patients, AVM obliteration was confirmed after 2–4 SRS procedures at a median follow-up of 87 months (range 0.4–209 months). Five patients had near-total obliteration (volume reduction &gt; 75% but residual AVM). The actuarial rates of total obliteration after 2-stage SRS were 7%, 20%, 28%, and 36% at 3, 4, 5, and 10 years, respectively. The 5-year total obliteration rate after the initial staged volumetric SRS with a margin dose of 17 Gy or more was 62% (p = 0.001). Sixteen patients underwent additional SRS at a median interval of 61 months (range 33–113 months) after the initial 2-stage SRS. The overall rates of total obliteration after staged and repeat SRS were 18%, 45%, and 56% at 5, 7, and 10 years, respectively. Ten patients sustained hemorrhage after staged SRS, and 5 of these patients died. Three of 16 patients who underwent repeat SRS sustained hemorrhage after the procedure and died. Based on Kaplan-Meier analysis (excluding the second hemorrhage in the patient who had 2 hemorrhages), the cumulative rates of AVM hemorrhage after SRS were 4.3%, 8.6%, 13.5%, and 36.0% at 1, 2, 5, and 10 years, respectively. This corresponded to annual hemorrhage risks of 4.3%, 2.3%, and 5.6% for Years 0–1, 1–5, and 5–10 after SRS. Multiple hemorrhages before SRS correlated with a significantly higher risk of hemorrhage after SRS. Symptomatic adverse radiation effects were detected in 13% of patients, but no patient died as a result of an adverse radiation effect. Delayed cyst formation did not occur in any patient after SRS.</p>
<p style="text-align: justify;">Conclusions. Prospective volume-staged SRS for large AVMs unsuitable for surgery has potential benefit but often requires more than 2 procedures to complete the obliteration process. To have a reasonable chance of benefit, the minimum margin dose should be 17 Gy or greater, depending on the AVM location. In the future, prospective volumestaged SRS followed by embolization (to reduce flow, obliterate fistulas, and occlude associated aneurysms) may improve obliteration results and further reduce the risk of hemorrhage after SRS.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.neurosurgery-blog.com/archives/3692/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Multisession Radiosurgery for Optic Nerve Sheath Meningiomas</title>
		<link>http://www.neurosurgery-blog.com/archives/3418</link>
		<comments>http://www.neurosurgery-blog.com/archives/3418#comments</comments>
		<pubDate>Mon, 21 Nov 2011 23:00:55 +0000</pubDate>
		<dc:creator>cba</dc:creator>
				<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Outcome]]></category>
		<category><![CDATA[radiosurgery]]></category>
		<category><![CDATA[CyberKnife]]></category>
		<category><![CDATA[Optic nerve sheath meningiomas]]></category>
		<category><![CDATA[radiotherapy]]></category>

		<guid isPermaLink="false">http://www.neurosurgery-blog.com/?p=3418</guid>
		<description><![CDATA[Neurosurgery 69:1116–1123, 2011 DOI: 10.1227/NEU.0b013e31822932fe 
Traditional treatment options for optic nerve sheath meningiomas (ONSMs) include observation, surgery, and radiotherapy, but to date none of these has become the clear treatment of choice.
OBJECTIVE: To evaluate the effectiveness and safety of multisession radiosurgery for ONSMs.
METHODS: From May 2004 to June 2008, 21 patients with ONSMs were treated [...]]]></description>
			<content:encoded><![CDATA[<p style="text-align: justify;"><strong><a href="http://www.neurosurgery-blog.com/wp-content/uploads/2011/11/Multisession_Radiosurgery_for_Optic_Nerve_Sheath-1.jpg"><img class="alignleft size-thumbnail wp-image-3420" title="Multisession_Radiosurgery_for_Optic_Nerve_Sheath-1" src="http://www.neurosurgery-blog.com/wp-content/uploads/2011/11/Multisession_Radiosurgery_for_Optic_Nerve_Sheath-1-150x150.jpg" alt="" width="150" height="150" /></a>Neurosurgery 69:1116–1123, 2011 DOI: 10.1227/NEU.0b013e31822932fe </strong><br />
Traditional treatment options for optic nerve sheath meningiomas (ONSMs) include observation, surgery, and radiotherapy, but to date none of these has become the clear treatment of choice.<br />
OBJECTIVE: To evaluate the effectiveness and safety of multisession radiosurgery for ONSMs.<br />
METHODS: From May 2004 to June 2008, 21 patients with ONSMs were treated by radiosurgery using the frameless CyberKnife system. Patient age ranged from 36 to 73 years (mean, 54 years). All patients were treated using multisession radiosurgery, with 5 fractions of 5 Gy each to a total dose of 25 Gy prescribed to the 75% to 85% isodose line. Patients were evaluated for tumor growth control and visual function.<br />
RESULTS: The median pretreatment tumor volume was 2.8 mL (range, 0.3-23 mL). The mean follow-up was 30 months (range, 11-68 months). All patients tolerated treatment well, with only 1 patient in whom a mild optic neuropathy developed (which remitted after systemic steroid therapy). No other acute or late radiation-induced toxicities were observed. No patients showed ONSM progression on follow-up magnetic resonance imaging. Two patients (10%) had a partial response. No patients had worsening of visual function; visual function was stable in 65% and improved in 35% of patients.<br />
CONCLUSION: Multisession radiosurgery for ONSMs was found to be safe and effective. The preliminary results from this study, in terms of growth control, visual function improvement, and toxicity, are quite promising. Further investigations are warranted.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.neurosurgery-blog.com/archives/3418/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Management of large vestibular schwannoma. Part II. Primary Gamma Knife surgery: radiological and clinical aspects</title>
		<link>http://www.neurosurgery-blog.com/archives/3365</link>
		<comments>http://www.neurosurgery-blog.com/archives/3365#comments</comments>
		<pubDate>Sun, 06 Nov 2011 23:00:00 +0000</pubDate>
		<dc:creator>cba</dc:creator>
				<category><![CDATA[Oncology]]></category>
		<category><![CDATA[radiosurgery]]></category>
		<category><![CDATA[facial nerve]]></category>
		<category><![CDATA[Gamma Knife surgery]]></category>
		<category><![CDATA[hearing]]></category>
		<category><![CDATA[large vestibular schwannoma]]></category>
		<category><![CDATA[Stereotactic radiosurgery]]></category>
		<category><![CDATA[volume measurement]]></category>

		<guid isPermaLink="false">http://www.neurosurgery-blog.com/?p=3365</guid>
		<description><![CDATA[J Neurosurg 115:885–893, 2011.DOI: 10.3171/2011.6.JNS101963
In large vestibular schwannomas (VSs), microsurgery is the main treatment option. A wait-and-scan policy or radiosurgery are generally not recommended given concerns of further lesion growth or increased mass effect due to transient swelling. Note, however, that some patients do not present with symptomatic mass effect or may still have serviceable [...]]]></description>
			<content:encoded><![CDATA[<p><strong><a href="http://www.neurosurgery-blog.com/wp-content/uploads/2011/11/Management-of-large-vestibular-schwannoma.-Part-II.jpg"><img class="alignleft size-thumbnail wp-image-3369" title="Management of large vestibular schwannoma. Part II" src="http://www.neurosurgery-blog.com/wp-content/uploads/2011/11/Management-of-large-vestibular-schwannoma.-Part-II-150x150.jpg" alt="" width="150" height="150" /></a>J Neurosurg 115:885–893, 2011.DOI: 10.3171/2011.6.JNS101963</strong></p>
<p style="text-align: justify;">In large vestibular schwannomas (VSs), microsurgery is the main treatment option. A wait-and-scan policy or radiosurgery are generally not recommended given concerns of further lesion growth or increased mass effect due to transient swelling. Note, however, that some patients do not present with symptomatic mass effect or may still have serviceable hearing. Moreover, others may be old, suffer from severe comorbidity, or refuse any surgery. In this study the authors report the results in patients with large, growing VSs primarily treated with Gamma Knife surgery (GKS), with special attention to volumetric growth, control rate, and symptoms.</p>
<p style="text-align: justify;">Methods. The authors retrospectively analyzed 33 consecutive patients who underwent GKS for large, growing VSs, which were defined as &gt; 6 cm3 and at least indenting the brainstem. Patients with neurofibromatosis Type 2 were excluded from analysis, as were patients who had undergone previous treatment. Volume measurements were performed on contrast-enhanced T1-weighted MR images at the time of GKS and during follow-up. Medical charts were analyzed for clinical symptoms.</p>
<p style="text-align: justify;">Results. Radiological growth control was achieved in 88% of cases, clinical control (that is, no need for further treatment) in 79% of cases. The median follow-up was 30 months, and the mean VS volume was 8.8 cm3 (range 6.1–17.7 cm3). No major complications occurred, although ventriculoperitoneal shunts were placed in 2 patients. The preservation of serviceable hearing and facial and trigeminal nerve function was achieved in 58%, 91%, and 86% of patients, respectively, with any facial and trigeminal neuropathy being transient. In 92% of the patients presenting with trigeminal hypesthesia before GKS, the condition resolved during follow-up. No patient- or VS-related feature was correlated with growth.</p>
<p style="text-align: justify;">Conclusions. Primary GKS for large VSs leads to acceptable radiological growth rates and clinical control rates, with the chance of hearing preservation. Although a higher incidence of clinical control failure and postradiosurgical morbidity is noted, as compared with that for smaller VSs, primary radiosurgery is suitable for a selected group of patients. The absence of symptomatology due to mass effect on the brainstem or cerebellum is essential, as are close clinical and radiological follow-ups, because there is little reserve for growth or swelling.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.neurosurgery-blog.com/archives/3365/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Management of large vestibular schwannoma. Part I. Planned subtotal resection followed by Gamma Knife surgery: radiological and clinical aspects</title>
		<link>http://www.neurosurgery-blog.com/archives/3349</link>
		<comments>http://www.neurosurgery-blog.com/archives/3349#comments</comments>
		<pubDate>Thu, 03 Nov 2011 23:00:55 +0000</pubDate>
		<dc:creator>cba</dc:creator>
				<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Outcome]]></category>
		<category><![CDATA[Surgical technique]]></category>
		<category><![CDATA[radiosurgery]]></category>
		<category><![CDATA[facial nerve]]></category>
		<category><![CDATA[Gamma Knife surgery]]></category>
		<category><![CDATA[large vestibular schwannoma]]></category>
		<category><![CDATA[Microsurgery]]></category>
		<category><![CDATA[Stereotactic radiosurgery]]></category>
		<category><![CDATA[volume measurement]]></category>

		<guid isPermaLink="false">http://www.neurosurgery-blog.com/?p=3349</guid>
		<description><![CDATA[J Neurosurg 115:875–884, 2011. DOI: 10.3171/2011.6.JNS101958
In large vestibular schwannoma (VS), microsurgery is the main treatment option, and complete resection is considered the primary goal. However, previous studies have documented suboptimal facial nerve outcomes in patients who undergo complete resection of large VSs. Subtotal resection is likely to reduce the risk of facial nerve injury but [...]]]></description>
			<content:encoded><![CDATA[<p><strong><a href="http://www.neurosurgery-blog.com/wp-content/uploads/2011/11/Large-Schwannoma.jpg"><img class="alignleft size-thumbnail wp-image-3354" title="Large Schwannoma" src="http://www.neurosurgery-blog.com/wp-content/uploads/2011/11/Large-Schwannoma-150x150.jpg" alt="" width="150" height="150" /></a>J Neurosurg 115:875–884, 2011. DOI: 10.3171/2011.6.JNS101958</strong></p>
<p style="text-align: justify;">In large vestibular schwannoma (VS), microsurgery is the main treatment option, and complete resection is considered the primary goal. However, previous studies have documented suboptimal facial nerve outcomes in patients who undergo complete resection of large VSs. Subtotal resection is likely to reduce the risk of facial nerve injury but increases the risk of lesion regrowth. Gamma Knife surgery (GKS) can be performed to achieve long-term growth control of residual VS after incomplete resection. In this study the authors report on the results in patients treated using planned subtotal resection followed by GKS with special attention to volumetric growth, control rate, and symptoms.</p>
<p style="text-align: justify;">Methods. Fifty consecutive patients who underwent the combined treatment strategy of subtotal microsurgical removal and GKS for large VSs between 2002 and 2009 were retrospectively analyzed. Patients with neurofibromatosis Type 2 were excluded. Patient charts were reviewed for clinical symptoms. Audiograms were evaluated to classify hearing pre- and postoperatively. Preoperative and follow-up contrast-enhanced T1-weighted MR images were analyzed using volume-measuring software.</p>
<p style="text-align: justify;">Results. Surgery was performed via a translabyrinthine (25 patients) or retrosigmoid (25 patients) approach. The median follow-up was 33.8 months. Clinical control was achieved in 92% of the cases and radiological control in 90%. One year after radiosurgery, facial nerve function was good (House-Brackmann Grade I or II) in 94% of the patients. One of the two patients who underwent surgery to preserve hearing maintained serviceable hearing after resection followed by GKS.</p>
<p style="text-align: justify;">Conclusions. Considering the good tumor growth control and facial nerve function preservation as well as the possibility of preserving serviceable hearing and the low number of complications, subtotal resection followed by GKS can be the treatment option of choice for large VSs.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.neurosurgery-blog.com/archives/3349/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Long-term Outcomes After Gamma Knife Radiosurgery for Patients With a Nonfunctioning Pituitary Adenoma</title>
		<link>http://www.neurosurgery-blog.com/archives/3087</link>
		<comments>http://www.neurosurgery-blog.com/archives/3087#comments</comments>
		<pubDate>Mon, 29 Aug 2011 22:00:36 +0000</pubDate>
		<dc:creator>cba</dc:creator>
				<category><![CDATA[Pituitary]]></category>
		<category><![CDATA[radiosurgery]]></category>
		<category><![CDATA[gamma-knife]]></category>
		<category><![CDATA[hypopituitarism]]></category>
		<category><![CDATA[pituitary adenoma]]></category>

		<guid isPermaLink="false">http://www.neurosurgery-blog.com/?p=3087</guid>
		<description><![CDATA[Neurosurgery 69:284–293, 2011 DOI: 10.1227/NEU.0b013e31821bc44e
Nonfunctioning pituitary adenomas recur after microsurgery. Gamma Knife radiosurgery (GKRS) has been used to treat recurrent adenomas.
OBJECTIVE: To evaluate the long-term rates of tumor control and development of hypopituitarism in patients with nonfunctioning pituitary adenomas after GKRS.
METHODS: Forty-eight patients with a nonfunctioning pituitary adenoma treated between 1991 and 2004 at the [...]]]></description>
			<content:encoded><![CDATA[<p><strong><a href="http://www.neurosurgery-blog.com/wp-content/uploads/2011/08/Long_term_Outcomes_After_Gamma_Knife_Radiosurgery.jpg"><img class="alignleft size-thumbnail wp-image-3090" title="Long_term_Outcomes_After_Gamma_Knife_Radiosurgery" src="http://www.neurosurgery-blog.com/wp-content/uploads/2011/08/Long_term_Outcomes_After_Gamma_Knife_Radiosurgery-150x150.jpg" alt="" width="150" height="150" /></a>Neurosurgery 69:284–293, 2011 DOI: 10.1227/NEU.0b013e31821bc44e</strong></p>
<p style="text-align: justify;">Nonfunctioning pituitary adenomas recur after microsurgery. Gamma Knife radiosurgery (GKRS) has been used to treat recurrent adenomas.</p>
<p style="text-align: justify;">OBJECTIVE: To evaluate the long-term rates of tumor control and development of hypopituitarism in patients with nonfunctioning pituitary adenomas after GKRS.</p>
<p style="text-align: justify;">METHODS: Forty-eight patients with a nonfunctioning pituitary adenoma treated between 1991 and 2004 at the University of Virginia were studied. All patients had more than 4 years of clinical and imaging follow-up.</p>
<p style="text-align: justify;">RESULTS: All patients underwent follow-up imaging and endocrine evaluations, with a duration ranging from 50 to 215 months (median, 80.5 months) and 57 to 201 months (median, 95 months), respectively. New hormone deficiency after GKRS occurred in 19 of 48 patients (39%). Corticotropin/cortisol deficiency developed in 8% of patients, thyroid hormone deficiency in 20.8%, gonadotropin deficiency in 4.2%, growth hormone/insulin-like growth factor 1 in 16.7%, and diabetes insipidus in 2%. Panhypopituitarism including diabetes insipidus developed in 1 patient. Overall, control of tumor volume was 83%. Tumor volume decreased in 36 patients (75%), increased in 8 patients (17%), and was unchanged in 4 patients (8%). Tumor volumes greater than 5 mL at the time of GKRS were associated with a significantly greater rate of growth (P = .003) compared with an adenoma with a volume of 5 mL or less.</p>
<p style="text-align: justify;">CONCLUSION: GKRS resulted in a high and durable rate of tumor control in patients with a nonfunctioning pituitary adenoma. A higher preoperative tumor volume was associated with an increased rate of tumor growth.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.neurosurgery-blog.com/archives/3087/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Gamma Knife surgery for parasellar meningiomas: long-term results including complications, predictive factors, and progression-free survival</title>
		<link>http://www.neurosurgery-blog.com/archives/2759</link>
		<comments>http://www.neurosurgery-blog.com/archives/2759#comments</comments>
		<pubDate>Mon, 13 Jun 2011 22:00:26 +0000</pubDate>
		<dc:creator>cba</dc:creator>
				<category><![CDATA[Oncology]]></category>
		<category><![CDATA[radiosurgery]]></category>
		<category><![CDATA[cavernous sinus]]></category>
		<category><![CDATA[parasellar meningioma]]></category>
		<category><![CDATA[skull base]]></category>
		<category><![CDATA[Stereotactic radiosurgery]]></category>

		<guid isPermaLink="false">http://www.neurosurgery-blog.com/?p=2759</guid>
		<description><![CDATA[J Neurosurg 114:1571–1577, 2011. DOI: 10.3171/2011.1.JNS091939
Stereotactic radiosurgery serves as an important primary and adjuvant treatment option for patients with many types of intracranial meningiomas. This is particularly true for patients with parasellar meningiomas. In this study, the authors evaluated the outcomes of Gamma Knife surgery (GKS) used to treat parasellar meningiomas.
Methods. The study is a [...]]]></description>
			<content:encoded><![CDATA[<p><strong><a href="http://www.neurosurgery-blog.com/wp-content/uploads/2011/06/parasellar_meningiomaI.jpg"><img class="alignleft size-thumbnail wp-image-2761" title="parasellar_meningiomaI" src="http://www.neurosurgery-blog.com/wp-content/uploads/2011/06/parasellar_meningiomaI-150x150.jpg" alt="" width="150" height="150" /></a>J Neurosurg 114:1571–1577, 2011. DOI: 10.3171/2011.1.JNS091939</strong></p>
<p style="text-align: justify;">Stereotactic radiosurgery serves as an important primary and adjuvant treatment option for patients with many types of intracranial meningiomas. This is particularly true for patients with parasellar meningiomas. In this study, the authors evaluated the outcomes of Gamma Knife surgery (GKS) used to treat parasellar meningiomas.</p>
<p style="text-align: justify;">Methods. The study is a retrospective review of the outcomes in 138 patients with meningiomas treated at the University of Virginia from 1989 to 2006; all patients had a minimum follow-up of 24 months. There were 31 men and 107 women whose mean age was 54 years (range 19–85 years). Eighty-four patients had previously undergone resection. The mean pre-GKS tumor volume was 7.5 ml (range 0.2–54.8 ml). Clinical and radiographic evaluations were performed, and factors related to favorable outcomes in each case were assessed.</p>
<p style="text-align: justify;">Results. The mean follow-up duration was 84 months (median 75.5 months, range 24–216 months). In 118 patients (86%), the tumor volume was unchanged or had decreased at last follow-up. Kaplan-Meier analysis demonstrated radiographic progression-free survival at 5 and 10 years to be 95.4% and 69%, respectively. Fourteen patients (10%) developed new cranial nerve palsies following GKS. Factors associated with tumor control included younger age, a higher isodose, and smaller tumor volume. A longer follow-up duration was associated with either a decrease or increase in tumor volume. Fourteen patients (10%) experienced new or worsening cranial nerve deficits after treatment. Factors associated with this occurrence were larger pretreatment tumor volume, lower peripheral radiation dose, lower maximum dose, tumor progression, and longer follow-up.</p>
<p style="text-align: justify;">Conclusions. Gamma Knife surgery offers an acceptable rate of tumor control for parasellar meningiomas and accomplishes this with a low incidence of neurological deficits. Radiological control after radiosurgery is more likely in those patients with a smaller tumor volume and a higher prescription dose.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.neurosurgery-blog.com/archives/2759/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Gamma Knife surgery of meningiomas located in the posterior fossa: factors predictive of outcome and remission</title>
		<link>http://www.neurosurgery-blog.com/archives/2632</link>
		<comments>http://www.neurosurgery-blog.com/archives/2632#comments</comments>
		<pubDate>Sun, 15 May 2011 22:00:37 +0000</pubDate>
		<dc:creator>cba</dc:creator>
				<category><![CDATA[Oncology]]></category>
		<category><![CDATA[radiosurgery]]></category>
		<category><![CDATA[gamma-knife]]></category>
		<category><![CDATA[meningioma]]></category>
		<category><![CDATA[posterior fossa]]></category>
		<category><![CDATA[predictor]]></category>
		<category><![CDATA[skull base]]></category>

		<guid isPermaLink="false">http://www.neurosurgery-blog.com/?p=2632</guid>
		<description><![CDATA[J Neurosurg 114:1399–1409, 2011. DOI: 10.3171/2010.11.JNS101193
Although numerous studies have analyzed the role of stereotactic radiosurgery for intracranial meningiomas, few studies have assessed outcomes of posterior fossa meningiomas after stereotactic radiosurgery. In this study, the authors evaluate the outcomes of posterior fossa meningiomas treated with Gamma Knife surgery (GKS). The authors also assess factors predictive of [...]]]></description>
			<content:encoded><![CDATA[<p><strong><a href="http://www.neurosurgery-blog.com/wp-content/uploads/2011/05/PFMeningioma.jpg"><img class="alignleft size-thumbnail wp-image-2634" title="PFMeningioma" src="http://www.neurosurgery-blog.com/wp-content/uploads/2011/05/PFMeningioma-150x150.jpg" alt="" width="150" height="150" /></a>J Neurosurg 114:1399–1409, 2011. DOI: 10.3171/2010.11.JNS101193</strong></p>
<p style="text-align: justify;">Although numerous studies have analyzed the role of stereotactic radiosurgery for intracranial meningiomas, few studies have assessed outcomes of posterior fossa meningiomas after stereotactic radiosurgery. In this study, the authors evaluate the outcomes of posterior fossa meningiomas treated with Gamma Knife surgery (GKS). The authors also assess factors predictive of new postoperative neurological deficits and tumor progression.</p>
<p style="text-align: justify;">Methods. A retrospective review was performed of a prospectively compiled database documenting the outcomes of 152 patients with posterior fossa meningiomas treated at the University of Virginia from 1990 to 2006. All patients had a minimum follow-up of 24 months. There were 30 males and 122 females, with a median age of 58 years (range 12–82 years). Seventy-five patients were treated with radiosurgery initially, and 77 patients were treated with GKS after resection. Patients were assessed clinically and radiographically at routine intervals following GKS. Factors predictive of new neurological deficit following GKS were assessed via univariate and multivariate analysis, and Kaplan-Meier analysis and Cox multivariate regression analysis were used to assess factors predictive of tumor progression.</p>
<p style="text-align: justify;">Results. Patients had meningiomas centered over the tentorium (35 patients, 23%), cerebellopontine angle (43 patients, 28%), petroclival region (28 patients, 18%), petrous region (6 patients, 4%), and clivus (40 patients, 26%). The median follow-up was 7 years (range 2–16 years). The mean preradiosurgical tumor volume was 5.7 cm3 (range 0.3–33 cm3), and mean postradiosurgical tumor volume was 4.9 cm3 (range 0.1–33 cm3). At last follow-up, 55 patients (36%) displayed no change in tumor volume, 78 (51%) displayed a decrease in volume, and 19 (13%) displayed an increase in volume. Kaplan-Meier analysis demonstrated radiographic progression-free survival at 3, 5, and 10 years to be 98%, 96%, and 78%, respectively. In Cox multivariable analysis, pre-GKS covariates associated with tumor progression included age greater than 65 years (hazard ratio [HR] 3.24, 95% CI 1.12–9.37; p = 0.03) and a low dose to the tumor margin (HR 0.76, 95% CI 0.60–0.97; p = 0.03), and post-GKS covariates included shunt-dependent hydrocephalus (HR 25.0, 95% CI 3.72–100.0; p = 0.001). At last clinical follow-up, 139 patients (91%) demonstrated no change or improvement in their neurological condition, and 13 patients showed symptom deterioration (9%). In multivariate analysis, the only factors predictive of new or worsening symptoms were clival or petrous location (OR 4.0, 95% CI 1.1–13.7; p = 0.03).</p>
<p style="text-align: justify;">Conclusions. Gamma Knife surgery offers an acceptable rate of tumor control for posterior fossa meningiomas and accomplishes this with a low incidence of neurological deficits. In patients selected for GKS, tumor progression is associated with age greater than 65 years and decreasing dose to the tumor margin. Clival- or petrous-based locations are predictive of an increased risk of new or worsening neurological deficit following GKS.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.neurosurgery-blog.com/archives/2632/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Gamma Knife radiosurgery for larger-volume vestibular schwannomas</title>
		<link>http://www.neurosurgery-blog.com/archives/2382</link>
		<comments>http://www.neurosurgery-blog.com/archives/2382#comments</comments>
		<pubDate>Tue, 22 Mar 2011 05:00:26 +0000</pubDate>
		<dc:creator>cba</dc:creator>
				<category><![CDATA[Oncology]]></category>
		<category><![CDATA[radiosurgery]]></category>
		<category><![CDATA[Acoustic neuroma]]></category>
		<category><![CDATA[gamma-knife]]></category>
		<category><![CDATA[Stereotactic radiosurgery]]></category>
		<category><![CDATA[Vestibular schwannoma]]></category>

		<guid isPermaLink="false">http://www.neurosurgery-blog.com/?p=2382</guid>
		<description><![CDATA[J Neurosurg 114:801–807, 2011.DOI: 10.3171/2010.8.JNS10674
Stereotactic radiosurgery (SRS) is an important management option for patients with small- and medium- sized vestibular schwannomas. To assess the potential role of SRS in larger tumors, the authors reviewed their recent experience.
Methods. Between 1994 and 2008, 65 patients with vestibular schwannomas between 3 and 4 cm in one extracanalicular maximum [...]]]></description>
			<content:encoded><![CDATA[<p><strong><a href="http://www.neurosurgery-blog.com/wp-content/uploads/2011/03/GK-VS.jpg"><img class="alignleft size-medium wp-image-2386" title="GK-VS" src="http://www.neurosurgery-blog.com/wp-content/uploads/2011/03/GK-VS-254x300.jpg" alt="" width="203" height="240" /></a>J Neurosurg 114:801–807, 2011.DOI: 10.3171/2010.8.JNS10674</strong></p>
<p style="text-align: justify;">Stereotactic radiosurgery (SRS) is an important management option for patients with small- and medium- sized vestibular schwannomas. To assess the potential role of SRS in larger tumors, the authors reviewed their recent experience.</p>
<p style="text-align: justify;">Methods. Between 1994 and 2008, 65 patients with vestibular schwannomas between 3 and 4 cm in one extracanalicular maximum diameter (median tumor volume 9 ml) underwent Gamma Knife surgery. Seventeen patients (26%) had previously undergone resection.</p>
<p style="text-align: justify;">Results. The median follow-up duration was 36 months (range 1–146 months). At the first planned imaging follow-up at 6 months, 5 tumors (8%) were slightly expanded, 53 (82%) were stable in size, and 7 (11%) were smaller. Two patients (3%) underwent resection within 6 months due to progressive symptoms. Two years later, with 63 tumors overall after the 2 post-SRS resections, 16 tumors (25%) had a volume reduction of more than 50%, 22 (35%) tumors had a volume reduction of 10–50%, 18 (29%) were stable in volume (volume change &lt; 10%), and 7 (11%) had larger volumes (5 of the 7 patients underwent resection and 1 of the 7 underwent repeat SRS). Eighteen (82%) of 22 patients with serviceable hearing before SRS still had serviceable hearing after SRS more than 2 years later. Three patients (5%) developed symptomatic hydrocephalus and underwent placement of a ventriculoperitoneal shunt. In 4 patients (6%) trigeminal sensory dysfunction developed, and in 1 patient (2%) mild facial weakness (House-Brackmann Grade II) developed after SRS. In univariate analysis, patients who had a previous resection (p = 0.010), those with a tumor volume exceeding 10 ml (p = 0.05), and those with Koos Grade 4 tumors (p = 0.02) had less likelihood of tumor control after SRS.</p>
<p style="text-align: justify;">Conclusions. Although microsurgical resection remains the primary management choice in patients with low comorbidities, most vestibular schwannomas with a maximum diameter less than 4 cm and without significant mass effect can be managed satisfactorily with Gamma Knife radiosurgery.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.neurosurgery-blog.com/archives/2382/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Decision analysis of treatment options for vestibular schwannoma</title>
		<link>http://www.neurosurgery-blog.com/archives/2172</link>
		<comments>http://www.neurosurgery-blog.com/archives/2172#comments</comments>
		<pubDate>Mon, 07 Feb 2011 05:00:00 +0000</pubDate>
		<dc:creator>cba</dc:creator>
				<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Outcome]]></category>
		<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[radiosurgery]]></category>
		<category><![CDATA[Acoustic neuroma]]></category>
		<category><![CDATA[decision analysis]]></category>
		<category><![CDATA[radiosurgery • microsurgery]]></category>
		<category><![CDATA[Vestibular schwannoma]]></category>

		<guid isPermaLink="false">http://www.neurosurgery-blog.com/?p=2172</guid>
		<description><![CDATA[J Neurosurg 114:400–413, 2011. (DOI: 10.3171/2010.3.JNS091802)
Widespread use of MR imaging has contributed to the more frequent diagnosis of vestibular schwannomas (VSs). These tumors represent 10% of primary adult intracranial neoplasms, and if they are symptomatic, they usually present with hearing loss and tinnitus. Currently, there are 3 treatment options for quality of life (QOL): wait [...]]]></description>
			<content:encoded><![CDATA[<p><strong><a href="http://www.neurosurgery-blog.com/wp-content/uploads/2011/02/VS.jpg"><img class="alignleft size-thumbnail wp-image-2175" title="VS" src="http://www.neurosurgery-blog.com/wp-content/uploads/2011/02/VS-150x150.jpg" alt="" width="150" height="150" /></a>J Neurosurg 114:400–413, 2011. (DOI: 10.3171/2010.3.JNS091802)</strong></p>
<p style="text-align: justify;">Widespread use of MR imaging has contributed to the more frequent diagnosis of vestibular schwannomas (VSs). These tumors represent 10% of primary adult intracranial neoplasms, and if they are symptomatic, they usually present with hearing loss and tinnitus. Currently, there are 3 treatment options for quality of life (QOL): wait and scan, microsurgery, and radiosurgery. In this paper, the authors’ purpose is to determine which treatment modality yields the highest QOL at 5- and 10-year follow-up, considering the likelihood of recurrence and various complications.</p>
<p style="text-align: justify;">Methods. The MEDLINE, Embase, and Cochrane online databases were searched for English-language articles published between 1990 and June 2008, containing key words relating to VS. Data were pooled to calculate the prevalence of treatment complications, tumor recurrence, and QOL with various complications. For parameters in which incidence varied with time of follow-up, the authors used meta-regression to determine the mean prevalence rates at a specified length of follow-up. A decision-analytical model was constructed to compare 5- and 10-year outcomes for a patient with a unilateral tumor and partially intact hearing. The 3 treatment options, wait and scan, microsurgery, and radiosurgery, were compared.</p>
<p style="text-align: justify;">Results. After screening more than 2500 abstracts, the authors ultimately included 113 articles in this analysis. Recurrence, complication rates, and onset of complication varied with the treatment chosen. The relative QOL at the 5-year follow-up was 0.898 of normal for wait and scan, 0.953 for microsurgery, and 0.97 for radiosurgery. These differences are significant (p &lt; 0.0052). Data were too scarce at the 10-year follow-up to calculate significant differences between the microsurgery and radiosurgery strategies.</p>
<p style="text-align: justify;">Conclusions. At 5 years, patients treated with radiosurgery have an overall better QOL than those treated with either microsurgery or those investigated further with serial imaging. The authors found that the complications associated with wait-and-scan and microsurgery treatment strategies negatively impacted patient lives more than the complications from radiosurgery. One limitation of this study is that the 10-year follow-up data were too limited to analyze, and more studies are needed to determine if the authors’ results are still consistent at 10 years.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.neurosurgery-blog.com/archives/2172/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Results Following Gamma Knife Radiosurgical Anterior Capsulotomies for Obsessive Compulsive Disorder</title>
		<link>http://www.neurosurgery-blog.com/archives/2066</link>
		<comments>http://www.neurosurgery-blog.com/archives/2066#comments</comments>
		<pubDate>Fri, 14 Jan 2011 05:00:24 +0000</pubDate>
		<dc:creator>cba</dc:creator>
				<category><![CDATA[Functional]]></category>
		<category><![CDATA[radiosurgery]]></category>
		<category><![CDATA[Capsulotomy]]></category>
		<category><![CDATA[Obsessive compulsive disorder]]></category>

		<guid isPermaLink="false">http://www.neurosurgery-blog.com/?p=2066</guid>
		<description><![CDATA[Neurosurgery 68:28–33, 2011 DOI: 10.1227/NEU.0b013e3181fc5c8b
Obsessive compulsive disorder (OCD), in its severe form, can cause tremendous disability for affected patients.
OBJECTIVE: To evaluate the results following bilateral radiosurgical anterior capsulotomy for severe medically refractory OCD.
METHODS: We performed gamma knife anterior capsulotomy (GKAC) on 3 patients with extreme, medically intractable OCD. According to our protocol, all patients were [...]]]></description>
			<content:encoded><![CDATA[<p><strong><a href="http://www.neurosurgery-blog.com/wp-content/uploads/2011/01/capsulotomy.jpg"><img class="alignleft size-thumbnail wp-image-2067" title="capsulotomy" src="http://www.neurosurgery-blog.com/wp-content/uploads/2011/01/capsulotomy-150x150.jpg" alt="" width="150" height="150" /></a>Neurosurgery 68:28–33, 2011 DOI: 10.1227/NEU.0b013e3181fc5c8b</strong></p>
<p style="text-align: justify;">Obsessive compulsive disorder (OCD), in its severe form, can cause tremendous disability for affected patients.</p>
<p style="text-align: justify;">OBJECTIVE: To evaluate the results following bilateral radiosurgical anterior capsulotomy for severe medically refractory OCD.</p>
<p style="text-align: justify;">METHODS: We performed gamma knife anterior capsulotomy (GKAC) on 3 patients with extreme, medically intractable OCD. According to our protocol, all patients were evaluated by at least 2 psychiatrists who recommended surgery. The patient had to request the procedure, and had to have severe OCD according to the Yale-Brown Obsessive Compulsive Scale (YBOCS). Patient ages were 37, 55, and 40 years, and pre-radiosurgery YBOCS scores were 34/40, 39/40, and 39/40. Bilateral lesions were created with 2 4-mm isocenters to create an oval volume in the ventral internal capsule at the putaminal midpoint. A maximum dose of 140 or 150 Gy was used.</p>
<p style="text-align: justify;">RESULTS: There was no morbidity after the procedure, and all patients returned immediately to baseline function. All patients noted significant functional improvements, and reduction in OCD behavior. Follow-up was at 55, 42, and 28 months. The first patient reduced her YBOCS score from 34 to 24. One patient with compulsive skin picking and an open wound had later healing of the chronic wound and a reduction in the YBOCS score from 39 to 8. At 28 months, the third patient is living and working independently, and her YBOCS score is 18.</p>
<p style="text-align: justify;">CONCLUSION: Within a strict protocol, gamma knife radiosurgery provided improvement of OCD behavior with no adverse effects. This technique should be evaluated further in patients with severe and disabling behavioral disorders.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.neurosurgery-blog.com/archives/2066/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

